Comparison of CD_4~+ T lymphocyte, Th1, Th2 for immune factors therapeutic reaction of malignant tumor patients after chemotherapy
- VernacularTitle:恶性肿瘤化疗后CD_4~+T细胞及Th1细胞、Th2细胞对免疫因子治疗的反应
- Author:
Yuansheng ZHANG
;
Xiaodong GU
;
Xianhua YIN
;
Yi PEI
- Publication Type:Journal Article
- Keywords:
Malignant tumor;
Immune factors;
Treatment
- From:
Cancer Research and Clinic
1997;0(03):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the adjustment of interleukin II combining lifein for CD+4 T lymphocyte, Th1 and Th2 of patients with malignant tumor. Methods CD+4 T lymphocyte were measured by flow cytometer. Th1 lymphocyte and Th2 lymphocyte were measured by ELISA. Thirty- eight patients with malignant tumor were enrolled in the study. Interleukin II were administered at the dose of 500 000 U, i.h Qd, from day 1 to day 5. Lifein were administered at the dose of 10mg/d, i.m Qd, from day 6 to day 21 or form day 6 to day 27. The count of CD+4 T lymphocyte, Th1 lymphocyte and Th2 lymphocyte were studied before treatment, 2 weeks and 1 month after treatment. Conduct ANOYA using SPSS software. Results The expression of CD+4 T lymphocyte in patients as with increase tendency. The counts of Th1 lymphocyte, Th2 lymphocyte and Th1/Th2 were not significantly different after treatment. Conclusions The dose of this treatment could enhance the count of CD+4 T, but it could not adjust the count of Th1 lymphocyte, Th2 lymphocyte. The target of treatment about interleukin II combining lifein for patients with malignant tumor is CD+4 T lymphocyte's other subsets.
